Key Takeaways Livmarli continues to be MIRM's top growth engine, with 1H 2025 sales up 79.1% year over year.Mirum raised its 2025 revenue guidance to $490-$510 million, citing strong product momentum.Cholbam and Ctexli sales also rose, adding to Mirum's expanding rare-disease drug portfolio.Mirum Pharmaceuticals’ (MIRM) lead product, Livmarli (maralixibat), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the company.Livmarli, an orally administered ileal b ...

Key Takeaways CorMedix launched DefenCath in 2024, generating $78.8M in H1 2025 revenues and raising guidance.CRMD acquired Melinta for $300M, adding seven marketed therapies and diversifying beyond DefenCath.MIRM's Livmarli posted $161.4M H1 2025 sales, but revenue reliance and competition pose key risks.CorMedix (CRMD) and Mirum Pharmaceuticals (MIRM) are pursuing treatments for underserved medical conditions where existing therapies are limited or nonexistent. Both companies are carving out niches in are ...